The part people forget when they're comparing Mazdutide trial reports: week 12 labs are where things stop moving in the same direction, and the numbers don't always cooperate.
Common pattern in a 48-week blinded Mazdutide trial — fasting glucose 104 → 91 mg/dL, A1c 5.7 → 5.4, weight down 6.8 kg by that point. Appetite noticeably lower, no vomiting. CRP dropping too, which reads as a good sign on paper.
Then the surprise: ALT drifting up, 24 → 41 U/L, and AST 20 → 28. Site coordinators tend to wave it off with "within range," which is technically true and also not really an answer.
Worth knowing before comparing notes with anyone further along: is that early enzyme bump just the usual arc — up a little around week 12, settled by week 24? Or is it more tied to how fast the weight comes off? Curious if anyone past the halfway mark in a blinded trial saw the same thing and what happened by the next draw.